^
Association details:
| Biomarker: | ETV6-NTRK3 fusion |
|---|---|
| Cancer: | Fibrosarcoma |
| Regimen: | VAC (cyclophosphamide + dactinomycin + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
Excerpt:
The patient was a girl aged 2 years at the time of enrollment with an ETS variant 6 (ETV6)–neurotrophic receptor tyrosine kinase 3 (NTRK3) fusion, localized, infantile fibrosarcoma…She received vincristine, actinomycin D, and cyclophosphamide (VAC) for 2 cycles and experienced disease progression.
DOI:
10.1002/cncr.31701
Trial ID:
